At each post-Voraxaze® assessment time point, the median MTX concentration was <0.54 μmol/L, corresponding to a median reduction of ≥97% from pre-Voraxaze® measurements.2
Voraxaze® reduced plasma MTX concentrations by ≥97% within 15 minutes in all 22 treatment-evaluable patients.1
of patients taking Voraxaze® (20 of 22) achieved sustained reductions for up to 8 days1
of patients (10 of 22) achieved rapid and sustained clinically important reduction (RSCIR)1
Incidence of Grade 4 toxicity was significantly lower with early administration of Voraxaze®2
Incidence of mortality was significantly lower with early administration of Voraxaze®3
Patients can achieve clinically important reductions in plasma MTX concentrations within 15 minutes vs 5 to 11 days
Not every patient requires Voraxaze®, but experts have assembled recommendations to help guide treatment.
Explore the guidelines for the use and stocking of Voraxaze® so that you’re prepared in an emergency.